Cambridge Crystallographic Data Centre

STORM Therapeutics Expands R&D Leadership Team

Retrieved on: 
Tuesday, January 10, 2023
Storm, Cancer, Clinical trial, Cambridge Crystallographic Data Centre, Celltech, CMC, Computational chemistry, Drug discovery, Therapy, University of Cambridge, University, UCB, Enzyme, RME, Trial of the century, Royal Society, Patient, Ophthalmology, Neurology, Royal Society of Chemistry, Columbia University, Medicinal chemistry, UCLA, METTL3, Patent, Bachelor of Science, Senior, Doctor of Philosophy, RNA, Nobel Prize, DMPK, Pharmaceutical industry, Chemistry

Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.

Key Points: 
  • Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.
  • Newly promoted Vice President of Medicinal Chemistry, Beth Thomas has over 20 years of experience in medicinal and computational chemistry and joined STORM Therapeutics in 2016.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, said: "I am delighted to welcome Matthew to the leadership team at STORM.
  • Matthew Fyfe, Senior Vice President of STORM Therapeutics, commented: "I am excited to be joining this strong and experienced drug discovery and development team.

STORM Therapeutics Expands R&D Leadership Team

Retrieved on: 
Tuesday, January 10, 2023
Storm, Cancer, Clinical trial, Cambridge Crystallographic Data Centre, Celltech, CMC, Computational chemistry, Drug discovery, Therapy, University of Cambridge, University, UCB, Enzyme, RME, Trial of the century, Royal Society, Patient, Ophthalmology, Neurology, Royal Society of Chemistry, Columbia University, Medicinal chemistry, UCLA, METTL3, Patent, Bachelor of Science, Senior, Doctor of Philosophy, RNA, Nobel Prize, DMPK, Pharmaceutical industry, Chemistry

Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.

Key Points: 
  • Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.
  • Newly promoted Vice President of Medicinal Chemistry, Beth Thomas has over 20 years of experience in medicinal and computational chemistry and joined STORM Therapeutics in 2016.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, said: "I am delighted to welcome Matthew to the leadership team at STORM.
  • Matthew Fyfe, Senior Vice President of STORM Therapeutics, commented: "I am excited to be joining this strong and experienced drug discovery and development team.

LifeMine Therapeutics Expands Management Team with Appointments of Martin Stahl, Ph.D., as Chief Scientific Officer and Louis Plamondon, Ph.D., as Executive Vice President and Head of CMC

Retrieved on: 
Thursday, October 6, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Constellation, Philippe Ciais, Gemstone, Doctor of Philosophy, Therapy, Computer, Head, Cambridge Crystallographic Data Centre, ChemMedChem, Cell engineering, Multiple myeloma, Bortezomib, Patient, Pharmacy, CMC, Computational chemistry, Drug discovery, Multiplicity of infection, Negotiation, Harvard University, Journal, University of Freiburg, Medicinal chemistry, University, Biophysics, Journal of Medicinal Chemistry, Data science, Biochemistry, Fine chemical, Pharmaceutical industry, MorphoSys, Chemistry

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the appointments of Martin Stahl, Ph.D., as chief scientific officer and Louis Plamondon, Ph.D., as executive vice president and head of CMC.

Key Points: 
  • LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the appointments of Martin Stahl, Ph.D., as chief scientific officer and Louis Plamondon, Ph.D., as executive vice president and head of CMC.
  • Dr. Stahl, former global head of lead discovery at Roche, will also lead LifeMines operations at its European offices in Basel, Switzerland.
  • Martin and Louis are stellar additions to the LifeMine executive team and share in our vision to reinvent small molecule drug discovery through genomic search and retrieval from the biosphere, said Gregory Verdine, Ph.D., co-founder, president and chief executive officer of LifeMine.
  • Martin and Louis experience and expertise will only help further accelerate our efforts.